Back to top
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Inogen, Inc (INGN) - $25 value - yours FREE >>
Accelerate Diagnostics, Inc. (AXDX) - $25 value - yours FREE >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inogen, Inc (INGN) - $25 value - yours FREE >>
Accelerate Diagnostics, Inc. (AXDX) - $25 value - yours FREE >>
Image: Bigstock
ConforMIS (CFMS) Gets FDA Approval for iTotal Hip System
Medical technology company, ConforMIS, Inc. recently announced the receipt of FDA 510(k) clearance for its primary iTotal Hip replacement system.
The ConforMIS iTotal Hip system features proprietary iFit image-to-implant technology. The system utilizes the company’s patient-specific technology and single-use 3D printed instruments. The iTotal Hip system is expected to be launched in 2019.
Per management, standard hip replacement surgery involves challenges and risk of dislocation and discrepancies in leg length. The ConforMIS iTotal Hip system is designed to overcome these challenges and risks and improve outcomes as this is designed to match a patient’s anatomy. This product will expand the company’s product portfolio to address a broader orthopedic market.
We are bullish on the ConforMIS’ focus on the rapidly growing hip replacement market. Approximately 400,000 hip replacements were performed in the domestic market in 2016.
According to Data Bridge Market Research, the global hip replacement implants market is expected to reach a worth of $7.1 billion by 2024 at a CAGR of 3.6% during the 2017 to 2024 period.So, the company clearly has bountiful opportunities in this niche market.
According to a study of HealthDay over 10 years from 2000 to 2010, the number of hip replacements has sky rocketed from 138,700 in 2000 to 310,800 in 2010. So the company, in line with its peers Inogen, Inc. (INGN - Free Report) , Luminex Corporation and Accelerate Diagnostics, Inc. (AXDX - Free Report) , are taking strategic steps to gain traction in the untapped market.
ConforMIS is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to suit each patient’s unique anatomy.
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>